$3.47−0.04 (−1.14%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
GoodRx Holdings (GDRX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~1.7%/yr (FY21→FY25), net margin 3.8%, and free cash flow (~$93.9M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲0.6%
796.9
FY21→FY25CAGR +1.7%/yr
Net income ($M)▲85.7%
30.4
one-off year: see footnoteCAGR —
Free cash flow ($M)▼17.3%
93.9
FY21→FY25CAGR −10.2%/yr
Diluted EPS▲125.0%
0.09
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−12.9%
410.0mn → 357.0mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$74.0M
steady at 9.3% of revenue (+5.2% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
4¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 93.7% → 92.8%. Net margin 3.8% is above the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 785.2 | 796.9 | 792.3 | 750.3 | 766.6 | 745.4 | ▲0.6% | +1.7% |
Cost of revenue | 72.0 | 57.6 | 48.2 | 66.9 | 65.1 | 46.7 | ▲19.5% | +5.4% |
Gross profit | 713.2 | 739.3 | 744.1 | 683.3 | 701.5 | 698.7 | ▼0.7% | +1.4% |
Research & development | 116.8 | 121.0 | 123.7 | 135.8 | 143.1 | 125.9 | ▼2.2% | −1.0% |
Selling, general & admin | 107.6 | 114.0 | 117.9 | 125.5 | 144.8 | 154.7 | ▼3.3% | −7.4% |
Total operating expenses | 638.2 | 651.8 | 678.3 | 710.3 | 699.7 | 685.3 | ▼3.9% | −1.2% |
Operating incomefeeds ROC rank | 74.9 | 87.5 | 65.8 | −27.0 | 1.7 | 13.4 | ▲32.9% | +59.8% |
Other income, net | −33.5 | −31.0 | −34.4 | −28.6 | −25.0 | −23.6 | — | — |
Pretax income | 41.4 | 56.5 | 31.5 | −55.6 | −23.2 | −10.2 | ▲79.7% | — |
Income tax | 25.1 | 26.1 | 15.1 | −46.7 | 9.6 | 15.1 | ▲73.2% | +14.7% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 16.2 | 30.4 | 16.4 | −8.9 | −32.8 | −25.3 | ▲85.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.04 | 0.09 | 0.04 | −0.02 | −0.08 | −0.06 | ▲125.0% | — |
Diluted shares (mn) | 348.06 | 356.97 | 392.17 | 410.31 | 412.86 | 409.98 | ▼9.0% | −3.4% |
| Margins | ||||||||
Gross margin87th pct in Healthcare | 90.8% | 92.8% | 93.9% | 91.1% | 91.5% | 93.7% | ▼1.1pp | −1.0pp |
Operating margin | 9.5% | 11.0% | 8.3% | −3.6% | 0.2% | 1.8% | ▲2.7pp | +9.2pp |
Net margin45th pct in Healthcare | 2.1% | 3.8% | 2.1% | −1.2% | −4.3% | −3.4% | ▲1.8pp | +7.2pp |
† TTM = trailing four quarters through 2026-06-30.FY21 effective tax rate was −148% vs a 46% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was −41% vs a 46% norm for this window, likely a one-time item; see the filing.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was GoodRx Holdings' revenue last fiscal year?
GoodRx Holdings reported revenue of $796.9M in fiscal 2025, up 0.6% from fiscal 2024.
What was GoodRx Holdings' net income?
GoodRx Holdings reported net income of $30.4M in fiscal 2025, a net margin of 3.8%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

